Rein Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$0.92(as of Jun 22, 12:15 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Rein Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$0.92
Ticker SymbolRNTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees10
CountyUSA
Market Cap$78.3M

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Rein Therapeutics Inc In Our Stock Scanner

As of Jun 22, 2026
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.